Search Results - "Björkstrand, B."

Progress in haematopoietic stem cell transplantation for multiple myeloma by Gahrton, G., Björkstrand, B.

“… Gahrton G. & Björkstrand B. (Departments of Medicine and Hematology, Karolinska Institutet and Huddinge University Hospital, Huddinge, Sweden). Progress in…”
Get full text

Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry by Blimark, Cecilie Hveding, Turesson, Ingemar, Genell, Anna, Ahlberg, Lucia, Björkstrand, Bo, Carlson, Kristina, Forsberg, Karin, Juliusson, Gunnar, Linder, Olle, Mellqvist, Ulf-Henrik, Nahi, Hareth, Kristinsson, Sigurdur Y

“…Epidemiology and outcome of myeloma are mainly reported from large university centers and collaborative groups, and do not represent 'real-world' patients. The…”
Get full text

Long-term follow-up of gene-marked CD34 cells after autologous stem cell transplantation for multiple myeloma by Alici, E, Björkstrand, B, Treschow, A, Aints, A, Smith, C I E, Gahrton, G, Dilber, M S

“…Gene marking can be used to investigate if progenitor cells harvested from patients are contaminated with tumorigenic cells. It can also provide information…”
Get full text

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial by Iacobelli, S, de Wreede, L C, Schönland, S, Björkstrand, B, Hegenbart, U, Gruber, A, Greinix, H, Volin, L, Narni, F, Carella, A M, Beksac, M, Bosi, A, Milone, G, Corradini, P, Friberg, K, van Biezen, A, Goldschmidt, H, de Witte, T, Morris, C, Niederwieser, D, Garderet, L, Kröger, N, Gahrton, G

“…Previous studies have shown that obtaining complete hematologic remission (CR) in multiple myeloma is an important predictor of PFS and OS. This applies both…”
Get full text

Peroperative teicoplanin for prevention of gram-positive infections in neutropenic patients with indwelling central venous catheters : a randomized, controlled study by LJUNGMAN, P, HÄGGLUND, H, BJÖRKSTRAND, B, LÖNNQVIST, B, RINGDEN, O

“…A prospective, randomized, open study comparing two doses of teicoplanin with no therapy administered at the time of insertion of a central venous catheter was…”
Get full text

Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation by LARSSON, K, BJÖRKSTRAND, B, LJUNGMAN, P

“…Patients who receive transplants of autologous peripheral stem cells have a shorter duration of neutropenia than patients who receive autologous bone marrow…”
Get full text

Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients by HAMMARSTRÖM, V, PAUKSEN, K, BJÖRKSTRAND, B, SIMONSSON, B, ÖBERG, G, LJUNGMAN, P

“…The aims of this study were to assess long-term immunity and reimmunization responses against tetanus toxoid in recipients of autologous stem cell grafts and…”
Get full text

Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma : A retrospective case-matched study from the European group for blood and marrow transplantation by BJÖRKSTRAND, B, LJUNGMAN, P, GOLDSTONE, A. H, DE LAURENZI, A, MAJOLINO, I, MARCUS, R, PRENTICE, H. G, REMES, K, SAMSON, D, SUREDA, A, VERDONCK, L. F, VOLIN, L, SVENSSON, H, GAHRTON, G, HERMANS, J, ALEGRE, A, APPERLEY, J, BLADE, J, CARLSON, K, CAVO, M, FERRANT, A

“…A retrospective case-matched analysis was performed comparing 189 myeloma patients treated with allogeneic bone marrow transplantation (allo-BMT) with an equal…”
Get full text

Primary plasma cell leukemia and autologous stem cell transplantation by DRAKE, Mary B, IACOBELLI, Simona, VAN BIEZEN, Anja, MORRIS, Curly, APPERLEY, Jane F, NIEDERWIESER, Dietger, BJÖRKSTRAND, Bo, GAHRTON, Gösta

“…Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases. It has a poor prognosis compared to multiple…”
Get full text

Efficacy and outcome of autologous transplantation in rare myelomas by MORRIS, Curly, DRAKE, Mary, NIEDERWIESER, Dietger, GAHRTON, Gosta, APPERLEY, Jane, LACOBELLI, Simona, VAN BIEZEN, Anja, BJORKSTRAND, Bo, GOLDSCHMIDT, Hartmut, HAROUSSEAU, Jean-Luc, MORGAN, Gareth, DE WITTE, Theo

“…As rare myelomas, i.e. the IgD, IgE, IgM and non-secretory forms, constitute only a small proportion of any study, relatively little is known about their…”
Get full text

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres by Gahrton, G., Svensson, H., Cavo, M., Apperley, J., Bacigalupo, A., Björkstrand, B., Bladé, J., Cornelissen, J., De Laurenzi, A., Facon, T., Ljungman, P., Michallet, M., Niederwieser, D., Powles, R., Reiffers, J., Russell, N. H., Samson, D., Schaefer, U. W., Schattenberg, A., Tura, S., Verdonck, L. F., Vernant, J. P., Willemze, R., Volin for the European Group for Blood, L.

“…Out of 690 allogeneic matched sibling donor transplants for multiple myeloma reported to the European Group for Blood and Marrow Transplantation (EBMT)…”
Get full text

Role of stem cell transplantation in myeloma by Gahrton, G, Iacobelli, S, Björkstrand, B, Bourhis, J, Corradini, P, Crawley, C, Morris, C, Niederwieser, D

Get more information

European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma by Björkstrand, B

“…The European Group for Blood and Marrow Transplantation (EBMT) Myeloma Registry, established in 1987, contains data on 1,368 allogeneic and more than 8,000…”
Get more information

Lenograstim (glycosylated rHuG-CSF) post high-dose chemotherapy and PBPC transplant in breast cancer and NHL patients by Björkstrand, B., Ljungman, P., Juliusson, G., Villman, K., Cohen-Scali, S.

Get full text

Lenograstim (glycosylated rHuG-CSF) enables mobilization of enough PBPC in breast cancer and NHL patients from dose of 2.5 μg/kg/day by Björkstrand, B., Ljungman, P., Villman, K., Juliusson, G., Cohen-Scali, S.

Get full text

High-Dose Treatment With Autologous Stem Cell Transplantation in Multiple Myeloma: Past, Present, and Future by Björkstrand, Bo, Gahrton, Gösta

“…High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) has been used in the treatment of multiple myeloma since the early 1980s. Its…”
Get full text

The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants by GAHRTON, G, IACOBELLI, S, KRÖGER, N, LJUNGMAN, P, MICHALLET, M, RUSSELL, N. H, SAMSON, D, SCHATTENBERG, A, SIROHI, B, VERDONCK, L. F, VOLIN, L, ZANDER, A, APPERLEY, J, NIEDERWIESER, D, BANDINI, G, BJÖRKSTRAND, B, BLADE, J, BOIRON, J. M, CAVO, M, CORNELISSEN, J, CORRADINI, P

“…The impact of the donor gender on outcome in HLA-identical sibling donor hematopoietic stem cell transplantation for multiple myeloma was studied in a…”
Get full text

Unrelated donor stem cell transplantation after autologous transplantation : experience of a single center by ASCHAN, J, REMBERGER, M, CARLENS, S, MATTSSON, J, DILBER, M, LÖNNQVIST, B, BJÖRKSTRAND, B

“…Patients who do not respond to autologous stem cell transplantation (ASCT) have a poor prognosis. Concerns about toxicity limit the use of unrelated donor stem…”
Get full text

Allogeneic transplantation in multiple myeloma by Gahrton, Gösta, Björkstrand, Bo

Get full text

Benefit and Timing of Second Transplantations in Multiple Myeloma: Clinical Findings and Methodological Limitations in a European Group for Blood and Marrow Transplantation Registry Study by MORRIS, C, IACOBELLI, S, BRAND, R, BJORKSTRAND, B, DRAKE, M, NIEDERWIESER, D, GAHRTON, C

“…To use European Group for Blood and Marrow Transplantation registry data to assess the benefit and optimal timing of a double-autologous transplantation…”
Get full text